Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

R. Dent, Z. Shao, P. Schmid, J. Cortes, D.W. Cescon, S. Saji, K.H. Jung, T. Bachelot, S. Wang, E.M. Ramírez, G. Basaran, A. Stradella, R. Mathiba, S.-C. Chen, K. Shen, Á. Wéber, N. Battelli, N. Niikura, T. Luo, Y.S. Chae, N. Fischbach, G. Garbaos, A. Patera, K. Zhao, P. Vuković, M.J. Maxwell, T. Traina, on behalf of the TROPION-Breast02 investigators

Access to this e-print is sponsored by AstraZeneca. If you do not already have online access to this study, you may gain access by registering through this page.

Terms and Conditions applies.

Disclaimers: The information provided may contain indications that have not been approved in Hong Kong. AstraZeneca does not recommend off-label use in any manner other than that described in the labelling information.

Please note: You will not be charged for this reprint.